Clinical Trial Update: A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating three-drug combination therapy (encorafenib, cetuximab, pembrolizumab) versus pembrolizumab alone in previous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Braftovi (encorafenib) (encorafenib)
• Erbitux (cetuximab) (cetuximab)
• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING